Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic Therapy and Immunotherapy in NSCLC With Pleural Disease or MPM
NCT04836429Phase 1Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of porfimer sodium in non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of serious adverse events. Started Mar 2022; status: terminated.
02
Drugs
porfimer sodium
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04836429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836429.